Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
11
×
boston blog main
11
×
deals
11
×
life sciences
national blog main
boston top stories
biotech
clinical trials
san francisco blog main
national top stories
san francisco top stories
fda
alexion pharmaceuticals
boehringer ingelheim
eli lilly
investing
startups
autoimmune disorders
crispr
gene editing
hepatitis b
new york blog main
new york top stories
rna interference
roche
sanofi
vc
abbvie
akouos
allergan
allosteric
alnylam pharmaceutials
alnylam pharmaceuticals
alzheimer's disease
amyotrophic lateral sclerosis (als)
arrowhead pharmaceuticals
astellas pharmaceuticals
atlas venture
atopic dermatitis
avapritinib
What
medicines
11
×
drug
deal
disease
gene
new
pharma
research
therapeutics
ago
bio
biotech
called
cancer
candidate
companies
date
developing
dicerna
editing
fda
molecules
pact
pharmaceuticals
potential
rna
roche
stakes
synthetic
team
years
abandoning
abbvie
address
adds
affects
aims
alliance
allosteric
alternative
Language
unset
Current search:
medicines
×
deals
×
boston
×
" boston blog main "
×
@xconomy.com
4 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines